MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.400 -0.050 (-2.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
This biotech company is innovative, but the market demands more than that. 
Via The Motley Fool
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today ↗
The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Got Mashed on Monday ↗
The company announced a flotation of its common shares that is potentially quite dilutive. 
Via The Motley Fool
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street ↗
Time is running out for the company to mount a comeback. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Was Climbing Today ↗
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
Via The Motley Fool
News headline image
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 ↗
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Plummeted Today ↗
The company's top line nearly doubled. 
Via The Motley Fool
News headline image
What 7 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Friday? ↗
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening ↗
Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales. 
Via Benzinga
News headline image
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Iovance (IOVA) Q2 Revenue Jumps 93% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story